PIPELINE

DRUG
CANDIDATE
TARGET INDICATION PLATFORM DISCOVERY PRECLINICAL PhI
Dose Escalation
PhI
Proof Of Concept
PhII
Pivotal Study
RS-0139 Integrin NSCL CA SagittaTM Bir

Integrin Breast CA SagittaTM Bir

Integrin Prostate CA SagittaTM Bir

Integrin Ovarian CA SagittaTM Bir

Integrin Head & Neck CA SagittaTM Bir

RS-0337 HER2 Breast CA SagittaTM Dui

HER2 Stomach CA SagittaTM Dui

RS-0461 Integrin Ovarian CA SagittaTM Dui

RS-0625 Integrin Ovarian CA SagittaTM Bir

RS-0735 Undisclosed Pancreas CA SagittaTM Bir

DRUG TARGET INDICATION PLATFORM PHASE
RS-0139 Integrin NSCL CA SagittaTM Bir PhI Dose Escalation
RS-0139 Integrin Breast CA SagittaTM Bir Preclinical
RS-0139 Integrin Prostate CA SagittaTM Bir Preclinical
RS-0139 Integrin Ovarian CA SagittaTM Bir Preclinical
RS-0139 Integrin Head&Neck CA SagittaTM Bir Preclinical
RS-0337 HER2 Breast CA SagittaTM Dui Preclinical
RS-0337 HER2 Stomach CA SagittaTM Dui Preclinical
RS-0461 Integrin Ovarian CA SagittaTM Dui Preclinical
RS-0625 Integrin Ovarian CA SagittaTM Bir Preclinical
RS-0735 Undisclosed Pancreas CA SagittaTM Bir Preclinical
DRUG TARGET INDICATION PLATFORM PHASE
RS-0139 Integrin NSCL CA SagittaTM Bir PhI Dose
Escalation
RS-0139 Integrin Breast CA SagittaTM Bir Preclinical
RS-0139 Integrin Prostate CA SagittaTM Bir Preclinical
RS-0139 Integrin Ovarian CA SagittaTM Bir Preclinical
RS-0139 Integrin Head&Neck CA SagittaTM Bir Preclinical
RS-0337 HER2 Breast CA SagittaTM Dui Preclinical
RS-0337 HER2 Stomach CA SagittaTM Dui Preclinical
RS-0461 Integrin Ovarian CA SagittaTM Dui Preclinical
RS-0625 Integrin Ovarian CA SagittaTM Bir Preclinical
RS-0735 Undisclosed Pancreas CA SagittaTM Bir Preclinical